Clinical-Microbiomics A/S: Financial statements 2022
CVR: 37230634
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Clinical-Microbiomics A/S (CVR 37230634) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 18,987,402 and a net result of DKK -6,908,831 compared with DKK -1,722,969 the year before. That is an increase of 13.2% compared with the year before. Equity in the 2022 report amounted to DKK 119,542,612. The solvency ratio was 84.4%. The company had 32 employees in the financial year.
- Gross Profit
- DKK 18,987,402
- Profit/Loss
- DKK -6,908,831
- Equity
- DKK 119,542,612
- Total Assets
- DKK 141,634,833
- Employees
- 32
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 19M | -6.9M | 119.5M | 32 |
| 2021 | - | 16.8M | -1.7M | 2.8M | 26 |
| 2020 | - | 17M | 816K | -3.3M | 19 |
| 2019 | - | 13.2M | 107K | -4.1M | 16 |
| 2018 | - | 8.5M | -483K | -4.3M | 12 |
Official annual report
Keep an eye on Clinical-Microbiomics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of October 12, 2022, Torben Thomasen has joined the board of directors of Clinical-Microbiomics A/S.
As of July 1, 2022, Isabelle Valerie de Cremoux has joined the board of directors of Clinical-Microbiomics A/S.
Clinical-Microbiomics A/S has published its annual report for 2021. Gross profit came to DKK 16,768,941, and the net result was DKK -1,722,969.
About Clinical-Microbiomics A/S
Clinical-Microbiomics A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Clinical-Microbiomics ApS. The management consists of Anders Christian Neto de Sousa Grøn. The board consists of Manoj Nirmal Dadlani (chair), Bruce Harvey Grant, Caroline Popper and Isabelle Valerie de Cremoux. The company's owners include MANJIN ApS, VENDLER ApS and Health For Life Capital II Prima S.C.A. RAIF. The company has 32 employees (2026). In 2025, the company reported a gross profit of EUR 2,831,000 and a net result of EUR -2,586,000 compared with EUR -4,328,000 the year before. Equity in the 2025 report amounted to EUR 85,447,000.